Diabetes pills in Novo Nordesque Ribelsus cuts the risk of cardiovascular and blood vessels

Novo Nordsk On Saturday, birth control pills in diabetes showed the benefits of the cardiovascular and blood vessels in a late stage, which paves the way to become a new option for treatment for people with diabetes and heart disease.

The birth control pills have reduced the risk of death related to cardiovascular disease, cardiac and stroke by 14 % compared to the imaginary medication after average average in patients with diabetes and firm heart disease, with or without chronic kidney disease. Danish drug maker presented the results on Rybelsus, which has already approved for type 2 diabetes, at the annual scientific session of the American College of Heart Diseases in Chicago.

Stephen Gove, the company’s chief international medical official, said in an interview that Novo Nordisk has already submitted an application in the United States and the European Union to expand the approval of the birth control pills to include a reduction in the risk of serious cardiovascular complications.

RYBELSUS is oral formulation once a day to inject diabetes from Novo Nordisk, which is eaten once a week. Both treatment, in addition to the company’s injection in the company’s injection, contains the active ingredient.

Wegovy won in March 2024 with our approval to reduce the risk of major cardiovascular events in adults with cardiovascular disease who suffer from obesity or weight gain. But the pill data provided on Saturday indicates that patients who hesitate to injection, such as those who are afraid of needles, can soon reach treatment in a more convenient way.

“We don’t know that everyone wants an injection, whether painful or not, they want the option of oral medicine,” CNBC told CNBC. “We offer this option, so that you can get one or another, depending on what patients and professions in the field of health care believe in that joint discussion.”

The data comes as a scoop of other drug makers, including Elie Lily, Work on developing GLP-1 orally for diabetes, weight loss and other conditions, such as sleeping breathing.

The third stage examined the experience of a little more than 9,600 patients 50 years and over those who received either Rybelsus or the imaginary medicine, at the top of the standard treatment system, for a short four years. Nearly half of all patients have received medications called SGLT2 inhibitors, which are used primarily to reduce blood sugar in adults with type 2 diabetes, at some point during the experiment.

By the end of the trial, 12 % of the people who took Rybelsus and 13.8 % of those taking the fake end with experience in heart attack, blood vessels or stroke. This represents 14 % less total risk among those who took Rybelsus.

The researchers said that the reduced risks are in line with the benefits of the heart and blood vessels that were observed in eight previous experiments that include the injection GLP-1, which include vocations and other popular medicines, according to a statement from the American College of Heart Diseases. GLP-1S mimics certain bowel hormones to reduce appetite and regulate blood sugar, but also have other effects such as reducing inflammation.

The statement said that Rybelsus helped reduce the risk of 26 % non -fatal heart disease compared to imaginary therapy, which was the “main driver” of the total limit for the risk of heart complications and blood vessels in the experiment. The birth control pills also reduced the risk of non -fatal strokes by 12 %, and the heart -related death was 7 % compared to the placebo.

The statement added that there is a big difference between Rybelsus and EMPLO groups in the results of the kidney function. Gowh said the experiment was “clearly” designed to examine the benefits of birth control pills.

OzemPic is It has already been approved To treat chronic kidney disease in diabetics.

The most common side effects that were reported in the study were the issues of the digestive system, such as nausea, diarrhea and constipation, which rarely prompted patients to stop taking Rybelsus, according to the statement. These symptoms are compatible with the side effects of symptomide.

The statement said that similar results were seen in all sub -groups of patients – according to age and sex and between people who suffer from various health conditions at the beginning of the experiment.

Unlike its injection counterparts, Rybelsus should be taken on an empty stomach at least 30 minutes before breakfast with a small amount of water. Despite these requirements, the study provides “reassurance that patients were able to take the medicine according to the directions and reap the benefits of cardiovascular health from him,” said Dr. Darren McGueri, a professor of medicine at the UT Southweestern Medical Center and the first author of the study.